Charles River Laboratories International, Inc (CRL)

Charles River Laboratories International, Inc. is a healthcare company listed on the NYSE as common stock. It provides drug discovery, non-clinical development, and safety testing services to pharmaceutical, biotechnology, and related life sciences clients in the United States, Europe, Canada, the Asia Pacific, and other international markets. The company operates through three main segments. Its Research Models and Services division supplies rodents and purpose-bred rats and mice, along with supporting services such as genetically engineered models, insourcing solutions, research animal diagnostics, and cell therapy development and production. Discovery and Safety Assessment offers in vitro and in vivo services for preclinical research, safety testing, and related studies. Manufacturing Solutions focuses on testing and contract development and manufacturing services for pharmaceuticals and consumer products. Founded in 1947 and headquartered in Wilmington, Massachusetts, the company also participates in collaborations involving cancer immunotherapy, vaccine development, and non-clinical study support.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-CRL
$271.28
-19.7% Downside
Overvalued
$346.07
2.4% Upside
Fair
Fair
0.0%
February 24, 2027
406.4x
5.1x
4.1x
16.331 B
18.836 B
14.8%
98.9%
4.5
994.4%
Valuation • Fair Value

Charles River Laboratories International, Inc (NYSE-CRL) Fair Value by Valuation Model

Review the available estimates for Charles River Laboratories International, Inc (NYSE-CRL), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$271.28

Estimated downside of 19.7% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$273.62

Discounted cash flow valuation reference.

Ben Graham Formula Value

$9.31

Classic Ben Graham valuation formula reference.

Comps Fair Value

$268.94

Comparable-company valuation reference.

Analyst Price Target

$346.07

Analysts imply upside of 2.4%.

How to read these valuation models

Use the 6 available valuation references for Charles River Laboratories International, Inc (NYSE-CRL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Charles River Laboratories International, Inc (NYSE-CRL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

3.977 B

Current operating scale indicator.

Revenue Forecast

3.95 B

Forward revenue estimate.

EBITDA

909.4 M

Current operating profitability reference.

EBITDA Forecast

1.005 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Charles River Laboratories International, Inc (NYSE-CRL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Charles River Laboratories International, Inc (NYSE-CRL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.87

No elevated caution signal from this screen.

Altman Z-Score

4.5

Relatively strong balance-sheet zone.

FCF / Net Income

994.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Charles River Laboratories International, Inc (NYSE-CRL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Charles River Laboratories International, Inc (NYSE-CRL)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

February 24, 2027

Days to Earnings

103

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Charles River Laboratories International, Inc (NYSE-CRL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Charles River Laboratories International, Inc (NYSE-CRL) Stock Forecast & Technical Outlook

Review Charles River Laboratories International, Inc (NYSE-CRL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Charles River Laboratories International, Inc (NYSE-CRL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Charles River Laboratories International, Inc (NYSE-CRL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Charles River Laboratories International, Inc (NYSE-CRL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Charles River Laboratories International, Inc (NYSE-CRL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Charles River Laboratories International, Inc (NYSE-CRL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Charles River Laboratories International, Inc (NYSE-CRL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Charles River Laboratories International, Inc (NYSE-CRL) has a Strong Buy consensus, with 11 buy, 2 hold and 1 sell recommendations in the current data set.

Buy 11
Hold 2
Sell 1
FAQ • Fast Investor Answers

Charles River Laboratories International, Inc (NYSE-CRL) Stock FAQ

Data-supported answers about Charles River Laboratories International, Inc (NYSE-CRL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$271.28
Estimated downside 19.7%
Valuation Rating
Overvalued
Estimated downside of 19.7%
Analyst Target
$346.07
Implied upside 2.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Charles River Laboratories International, Inc (NYSE-CRL) is $271.28. This implies an estimated downside of 19.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 19.7% versus the current market price.

The available analyst price target for Charles River Laboratories International, Inc (NYSE-CRL) is $346.07. The analyst target implies estimated upside of 2.4%.

The current financial health read for Charles River Laboratories International, Inc (NYSE-CRL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Charles River Laboratories International, Inc (NYSE-CRL) is February 24, 2027.

The latest available data indicates no current dividend yield for Charles River Laboratories International, Inc (NYSE-CRL).

The current P/E ratio listed for Charles River Laboratories International, Inc (NYSE-CRL) is 406.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Charles River Laboratories International, Inc is 16.331 B.

The current enterprise value listed for Charles River Laboratories International, Inc is 18.836 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Charles River Laboratories International, Inc is NYSE-CRL, and the stock is listed on NYSE.

Charles River Laboratories International, Inc (NYSE-CRL) is listed on NYSE.

The current debt-to-total-capital ratio listed for Charles River Laboratories International, Inc is 14.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Charles River Laboratories International, Inc is 98.9%. Free float helps investors understand how much of the share base is available for public trading.